ReproCardio 2 Human iPS Cell-derived Cardiomyocytes

Catalog RCDC001N
Size 1x106 cells
Price
$850.00
$850.00
Availability In stock
Catalog
RCDC001N

Product Overview

Frozen human iPSC-derived cardiomyocytes for 96 well high throughput & high content analysis:

  • Frozen as single cell suspension with high viability and integrity
  • Can be grown in monolayer or aggregates according to your experimental needs
  • Functionally validated with various small molecule reference compounds that modulate cardiomyocyte physiology
  • Express cardiac ion channels and cardiomyocyte-specific markers
  • Contain no genetic modifications for purification or selection;  all natural
  • An assay medium for live cell imaging or reporter analysis is available separately

ReproCardio 2 cardiomyocytes are delivered as frozen single cells that retain structural and functional integrity, and high viability thanks to REPROCELL's proprietary freezing technology. The cells can be thawed and plated into monolayer or aggregates depending on your protocol / assay approach. Cultured monolayers and aggregates of ReproCardio 2 cardiomyocytes beat robustly, providing an excellent in vitro model of functional heart tissue.

RCDC001N: ReproCardio2 Cardiomyocytes

  • Derived from RNA-reprogrammed human iPS cell (healthy 32-year-old male) 
  • Frozen single cell suspension of mature cardiomyocytes
  • 1 x 106 cells (enough for >100 aggregates or monolayers in a single 96-well plate )
  • Stable "indefinitely" when stored in liquid nitrogen

Product Specifications

Product Name
ReproCardio 2 Human iPS Cell-derived Cardiomyocytes
Catalog Number
RCDC001N
Size
1x106 cells
Storage and Stability
Store cells in liquid nitrogen
Related Products
ReproCardio2 Culture Medium 2 (100 ml)
ReproCardio2 Assay Medium (100 ml)
ReproCoat
QTempo assay service


Presentations

  • Society for Biomolecular Sciences(SBS), 14th AnnualConference & Exhibition 2008 (St. Louis), poster session, April 2008.
  • IBC Asia's 4th Annual Stem Cells Asia Congress (Singapore), oral session, June 2008.
  • ELRIG and SBS Present: Drug Discovery (UK) poster session, September 2008.
  • Advances in Stem Cell Discoveries (San Francisco) oral session, September 2008.
  • Stem Cells: Drug Discovery and Therapeutics (London) oral session, February 2008.
  • Society for Biomolecular Science 15th Annual Conference (France), poster session, Best Poster 2009 Award-winning, April 2009.
  • Stem Cells and Regenerative Medicine Europe (UK), September 2009, Best Poster 2009 Award-winning.
  • MipTec Conference 2009, October 13-15, Basel Invited Lecture.
  • The 74th Annual Scientific Meeting of the Japanese Circulation Society (Kyoto), March 2010.
  • The 130th The Pharmaceutical Society of Japan (Okayama), March 2010.
  • The Society of Toxicology (SOT) 51st Annual Meeting (CA, USA), poster session, March 2012.
  • Safety Pharmacology Society (SPS), 13th annual meeting 2013 (Rotterdam, Netherlands), poster session, September 2013.
  • Automated Patch-Clamp systems and Ion Channel Expressing Cells 2013 (Tokyo), Verbal presentation 2013 Nov.
  • The 7th Takeda Science Foundation Symposium (Osaka), Poster presentation 2014 Jan

Publications

ReproCardio, ReproCardio2

  • Kido K; ito H; Yamamoto Y; Makita K; Uchida T. "Cytotoxicity of propofol in human induced pluripotent stem cell-derived cardiomyocytes." J Anesthesia 32:120 (2018)
  • Datta-Chaudhuri, Timir, Pamela Abshire, and Elisabeth Smela. "Packaging commercial CMOS chips for lab on a chip integration." Lab on a chip 14.10 (2014): 1753-1766.
  • Datta-Chaudhuri, Timir, Pamela Abshire, and Elisabeth Smela. "Packaging commercial CMOS chips for lab on a chip integration." Lab on a chip 14.10 (2014): 1753-1766.
  • Mandenius, Carl-Fredrik, and Thomas Meyer. "High-throughput screening assays to evaluate the cardiotoxic potential of drugs." High-Throughput Screening Methods in Toxicity Testing (2013): 403-420.
  • Scott, Clay W., Matthew F. Peters, and Yvonne P. Dragan. "Human induced pluripotent stem cells and their use in drug discovery for toxicity testing." Toxicology letters 219.1 (2013): 49-58.
  • Takeuchi, Akimasa, et al. "Microfabricated device for co-culture of sympathetic neuron and iPS-derived cardiomyocytes." Engineering in Medicine and Biology Society (EMBC), 2013 35th Annual International Conference of the IEEE. IEEE, 2013.
  • Asai, Yasuyuki, et al. "Combination of functional cardiomyocytes derived from human stem cells and a highly-efficient microelectrode array system: an ideal hybrid model assay for drug development." Current stem cell research & therapy 5.3 (2010): 227-232.
  • Asai, Y. "Direct measurement of the QT interval in stem cell-derived cardiomyocytes for the assessment of QT liability." Nihon yakurigaku zasshi. Folia pharmacologica Japonica 134.6 (2009): 320-324.
  • Szebenyi, Kornelia, et al. "Human pluripotent stem cells in pharmacological and toxicological screening: new perspectives for personalized medicine." Personalized Medicine 8.3 (2011): 347-364.

QTempo assay

  • Vidarsson, Hilmar, Johan Hyllner, and Peter Sartipy. "Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications."Stem Cell Reviews and Reports 6.1 (2010): 108-120.
  • Lecina, Marti, et al. "Scalable platform for human embryonic stem cell differentiation to cardiomyocytes in suspended microcarrier cultures." Tissue Engineering Part C: Methods 16.6 (2010): 1609-1619.
  • Phillips, Blaine W., and Jeremy M. Crook. "Pluripotent Human Stem Cells."BioDrugs 24.2 (2010): 99-108.

Product Specifications

Product Name
ReproCardio 2 Human iPS Cell-derived Cardiomyocytes
Catalog Number
RCDC001N
Size
1x106 cells
Storage and Stability
Store cells in liquid nitrogen
Related Products
ReproCardio2 Culture Medium 2 (100 ml)
ReproCardio2 Assay Medium (100 ml)
ReproCoat
QTempo assay service

Presentations

  • Society for Biomolecular Sciences(SBS), 14th AnnualConference & Exhibition 2008 (St. Louis), poster session, April 2008.
  • IBC Asia's 4th Annual Stem Cells Asia Congress (Singapore), oral session, June 2008.
  • ELRIG and SBS Present: Drug Discovery (UK) poster session, September 2008.
  • Advances in Stem Cell Discoveries (San Francisco) oral session, September 2008.
  • Stem Cells: Drug Discovery and Therapeutics (London) oral session, February 2008.
  • Society for Biomolecular Science 15th Annual Conference (France), poster session, Best Poster 2009 Award-winning, April 2009.
  • Stem Cells and Regenerative Medicine Europe (UK), September 2009, Best Poster 2009 Award-winning.
  • MipTec Conference 2009, October 13-15, Basel Invited Lecture.
  • The 74th Annual Scientific Meeting of the Japanese Circulation Society (Kyoto), March 2010.
  • The 130th The Pharmaceutical Society of Japan (Okayama), March 2010.
  • The Society of Toxicology (SOT) 51st Annual Meeting (CA, USA), poster session, March 2012.
  • Safety Pharmacology Society (SPS), 13th annual meeting 2013 (Rotterdam, Netherlands), poster session, September 2013.
  • Automated Patch-Clamp systems and Ion Channel Expressing Cells 2013 (Tokyo), Verbal presentation 2013 Nov.
  • The 7th Takeda Science Foundation Symposium (Osaka), Poster presentation 2014 Jan

Publications

ReproCardio, ReproCardio2

  • Kido K; ito H; Yamamoto Y; Makita K; Uchida T. "Cytotoxicity of propofol in human induced pluripotent stem cell-derived cardiomyocytes." J Anesthesia 32:120 (2018)
  • Datta-Chaudhuri, Timir, Pamela Abshire, and Elisabeth Smela. "Packaging commercial CMOS chips for lab on a chip integration." Lab on a chip 14.10 (2014): 1753-1766.
  • Datta-Chaudhuri, Timir, Pamela Abshire, and Elisabeth Smela. "Packaging commercial CMOS chips for lab on a chip integration." Lab on a chip 14.10 (2014): 1753-1766.
  • Mandenius, Carl-Fredrik, and Thomas Meyer. "High-throughput screening assays to evaluate the cardiotoxic potential of drugs." High-Throughput Screening Methods in Toxicity Testing (2013): 403-420.
  • Scott, Clay W., Matthew F. Peters, and Yvonne P. Dragan. "Human induced pluripotent stem cells and their use in drug discovery for toxicity testing." Toxicology letters 219.1 (2013): 49-58.
  • Takeuchi, Akimasa, et al. "Microfabricated device for co-culture of sympathetic neuron and iPS-derived cardiomyocytes." Engineering in Medicine and Biology Society (EMBC), 2013 35th Annual International Conference of the IEEE. IEEE, 2013.
  • Asai, Yasuyuki, et al. "Combination of functional cardiomyocytes derived from human stem cells and a highly-efficient microelectrode array system: an ideal hybrid model assay for drug development." Current stem cell research & therapy 5.3 (2010): 227-232.
  • Asai, Y. "Direct measurement of the QT interval in stem cell-derived cardiomyocytes for the assessment of QT liability." Nihon yakurigaku zasshi. Folia pharmacologica Japonica 134.6 (2009): 320-324.
  • Szebenyi, Kornelia, et al. "Human pluripotent stem cells in pharmacological and toxicological screening: new perspectives for personalized medicine." Personalized Medicine 8.3 (2011): 347-364.

QTempo assay

  • Vidarsson, Hilmar, Johan Hyllner, and Peter Sartipy. "Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications."Stem Cell Reviews and Reports 6.1 (2010): 108-120.
  • Lecina, Marti, et al. "Scalable platform for human embryonic stem cell differentiation to cardiomyocytes in suspended microcarrier cultures." Tissue Engineering Part C: Methods 16.6 (2010): 1609-1619.
  • Phillips, Blaine W., and Jeremy M. Crook. "Pluripotent Human Stem Cells."BioDrugs 24.2 (2010): 99-108.